Influence of Clearing Open-capsule Device on Refractive Predictability in Cataract Patients

Phase

N/A

Condition

Eye Disease

Vision Loss

Eye Disorders/infections

Treatment

N/A

Clinical Study ID

NCT04838730

CR-0719

Ages 50-80
All Genders

Study Summary

CleaRing is intended to reduce posterior capsular opacification in cataract patients. The device is intended to be implanted together with standard posterior chamber IOL during cataract surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria: The subject is between 50 and 80 years of age The subject is designated for cataractsurgery Eye designated for the study fulfills the following criteria:

Potentially able to achieve a good vision (by the opinion of the investigator)
ACD is at least 2.5mm (from epithelium)
Corneal astigmatism is at most 2.0 DPT
Axial length is between 22.0 and 26.0 mm
Able to obtain pupil dilation of at least 6.0 mm
Average keratometry values between 42.0 and 46.0 D Subject understands the studyrequirements and the treatment procedures and provides written Informed Consent beforeany study-specific tests or procedures are performed

Exclusion

Exclusion Criteria:

Subject diagnosed with glaucoma of any type or having intraocular pressure above 24mmHg
Subject who has undergone previous intraocular surgery in eye designated for the study
Subject with a corneal abnormality that would prevent stable and reliable refraction
Subject with weak or torn zonules
Subject with Pseudoexfoliation syndrome (PEX)
Subject with amblyopia
Subject with a retinal disease that in the opinion of the principal investigator wouldprevent stable and reliable refraction or might be worsened due to implantation of thedevice
Subject is diagnosed with active anterior segment intraocular inflammation
Subject is obligated to previous participation in another study with anyinvestigational drug or device within the past 30 days
Subject is pregnant

Study Design

January 01, 2019

January 01, 2023

Study Description

Study Design:

This study is a prospective, single-group, single-center, open-label study. Each study subject will be implanted with a CleaRing device together with SeeLens AF IOL in a single eye.

Study population:

Men and women designated for cataract surgery that meet the inclusion/exclusion criteria and provide written informed consent will be enrolled in the study.

Enrollment:

A total of 20 subjects will be enrolled.

Investigational sites:

Single-center study.

Duration of Subject participation:

The primary endpoint will be achieved when the study subject has completed a 1-month follow-up after the implantation of the CleaRing device.

Study Group:

Each subject will be implanted with a CleaRing device together with SeeLens AF IOL in a single eye.

Visits & Procedures Pre-operative visit: 0-3 months prior to the implantation procedure. The visit will include the subject's qualification assessment for inclusion/exclusion criteria as described above. Informed consent must be signed.

Complete anamnesis will be taken including the subject's medical complaints, medical history, medication use, and ophthalmic examinations.

Surgical procedure: Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.

Follow-up: All subjects will have regular follow-up visits at the following post-operative periods: 1 day, 7 days, and 1 month. All postoperative visits will include a complete ophthalmic examination, a record of medications used, and documentation of adverse events.

Connect with a study center

Wolfson
H̱olon,
Israel
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.